BioLife Solutions
BLFS · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$96.2M
Net margin
-4.8%
ROE
-1.2%
Revenue CAGR (2y)
+18.9%
EPS (FY2025)
-0.10
Net profit (FY2025)
$-4.6M
Ask MarketChacha about BLFS
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Jul 28, 2026
BLFS rose as it continued to trade toward the $31/share Repligen acquisition price announced July 22 (cash + stock deal, ~24% premium), hitting a new 52-week high amid the pending transaction.
- Jul 27, 2026
BLFS fell amid ongoing fairness probes by law firms into the adequacy of the Repligen acquisition price/process and recent analyst downgrades to Hold (e.g., TD Cowen, others) following the July 22 deal announcement.
- Jul 22, 2026
BioLife Solutions shares rose sharply after Repligen announced a $1.5 billion cash-and-stock acquisition of the company at $31 per share.
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $96.2M | $-4.6M | -0.10 | -4.8% | -1.2% |
| FY2024 | $74.6M | $-20.2M | -0.44 | -27.0% | -5.8% |
| FY2023 | $68.0M | $-68.0M | -1.55 | -100.0% | -20.1% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $28.5M | $45.1M* | 0.91 | — |
| 2026Q1 | $27.5M | $1.2M | 0.02 | 4.3% |
| 2025Q3 | $28.1M | $621,000 | 0.01 | 2.2% |
| 2025Q2 | $23.4M | $-15.8M | -0.33 | -67.6% |
| 2025Q1 | $22.1M | $-448,000 | 0.00 | -2.0% |
| 2024Q3 | $21.4M | $-1.7M | -0.04 | -8.0% |
| 2024Q2 | $19.7M | $-20.7M | -0.45 | -105.1% |
| 2024Q1 | $18.4M | $-10.2M | -0.22 | -55.4% |
| 2023Q3 | $23.6M | $-29.1M | -0.67 | -123.6% |
| 2023Q2 | $29.2M | $-10.2M | -0.23 | -34.9% |
| 2023Q1 | $37.7M | $-13.7M | -0.32 | -36.4% |
* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/6/2026material
- SEC8/6/2026
- SEC8/3/2026material
- SEC7/22/2026material
- SEC6/3/2026material
- SEC5/7/2026material
- SEC5/7/2026
- SEC4/28/2026
- SEC3/2/2026material
- SEC2/26/2026material
- SEC2/26/2026
- SEC1/12/2026material
- SEC1/9/2026material
2025
- SEC11/17/2025material
- SEC11/6/2025material
- SEC11/6/2025
- SEC8/21/2025material
- SEC8/7/2025material
- SEC8/7/2025
In the news
- Diamond Hill Capital Management LLC Investment Advisor Acquires New Stake in BioLife Solutions, Inc. $BLFSMarketBeat · 8/18/2026
- Short Interest in BioLife Solutions, Inc. (NASDAQ:BLFS) Rises By 59.1%MarketBeat · 8/18/2026
- BioLife Solutions (NASDAQ:BLFS) Reaches New 12-Month High - Should You Buy?MarketBeat · 8/17/2026
- BioLife’s Sharp Swing To Profit Might Change The Case For Investing In BioLife Solutions (BLFS)simplywall.st · 8/17/2026
- BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of "Hold" by BrokeragesMarketBeat · 8/16/2026
- Is BioLife Solutions (BLFS) A Bargain After Its Earnings Turnaround?simplywall.st · 8/14/2026
- BioLife Solutions (NASDAQ:BLFS) Hits New 12-Month High - Time to Buy?MarketBeat · 8/11/2026
- Why BioLife Solutions (BLFS) Is Up 7.8% After Swinging To Q2 Profitability And What's Nextsimplywall.st · 8/10/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.